Indications:

Heart failure

Contraindications:

is contraindicated in patients with known hypersensitivity all’enoximone or other components of the product. PERFAN is contraindicated also in valvular heart disease and severe obstructive; nell’ipovolemia serious unmatched in ventricular tachyarrhythmias and ventricular nell’aneurisma. In the absence of clinical experience in this regard, the use of PERFAN is not recommended in cases of myocardial infarction.

Adverse reactions:

Long-term oral treatment with enoximone has been reported to increase the mortality rate and enoximone is now only given intravenously for short-term use. Enoximone may cause ventricular and supraventricular tachyarrhythmias, ectopic beats, and hypotension. Adverse effects of enoximone affecting the gastrointestinal tract include diarrhoea, nausea, and vomiting. Other adverse effects include headache, insomnia, chills, oliguria, fever, urinary retention, and limb pain. There have been reports of thrombocytopenia and abnormal liver enzyme values.

Interactions:

In 385 patients treated with PERFAN no interactions were observed with other drugs, most patients received, in fact, as a concomitant or more of the following drugs: diuretics (amiloride, triamterene, furosemide and spironolactone), digitalis glycosides (digoxin) , potassium, antiarrhythmics (diltiazem, propranolol, lidocaine, nifedipine, procainamide and quinidine), vasodilators (captopril, hydralazine and nitrates), anticoagulants (warfarin and heparin), analgesics (ASA, paracetamol and codeine), sedatives (chloral hydrate, diazepam and lorazepam) and positive inotropic agents (dobutamine and dopamine).

Warnings:

Enoximone should be used with caution in patients with hypertrophic cardiomyopathy or severe obstructive aortic or pulmonary valvular disease. Blood pressure, heart rate, ECG, fluid and electrolyte status, and renal function should be monitored during therapy. Platelet count and liver enzyme values should also be monitored. The injection has a high pH (about 12) and must be diluted before use Extravasation should be avoided during administration. Doses may need to be reduced in hepatic or renal impairment .

Form:

SOLUTION FOR INJECTION